Home › Compare › CNLFF vs ABBV
CNLFF yields 14.90% · ABBV yields 3.06%● Live data
📍 CNLFF pulled ahead of the other in Year 1
Combined, CNLFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CNLFF + ABBV for your $10,000?
Canlan Ice Sports Corp. engages in the acquisition, development, lease, and operation of multi-purpose recreation and entertainment facilities in North America. The company operates through six segments: Ice/Field Sales and Internal Programming, Restaurant and Lounge Operations, Retail Sports Store Operations, Sponsorship, Space Rental, and Management and Consulting Services. It rents ice or field-time on a contract basis and organizes leagues and tournaments, as well as provides lessons and youth camps; operates restaurants and concession outlets; and operates sports stores that sell hockey, skating, and soccer equipment and apparel. The company also engages in the rental of indoor and exterior space to third party tenants; and manages recreation facilities owned by third parties, as well as offers sponsorship and advertising services. As of December 31, 2021, it owned, leased, and managed 18 facilities in Canada and the United States with 49 ice sheets; 7 indoor turf fields; and 24 multi-sport hard courts and outdoor beach volleyball courts. The company was formerly known as Canlan Investment Corporation and changed its name to Canlan Ice Sports Corp. in 1999. The company was incorporated in 1956 and is headquartered in Burnaby, Canada. Canlan Ice Sports Corp. is a subsidiary of Bartrac Investments Ltd.
Full CNLFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.